Posted by Michael Wonder on 07 Aug 2020
Rheumatoid arthritis drug Rinvoq gets insurance benefit
7 August 2020 - AbbVie Korea’s rheumatoid arthritis treatment Rinvoq (upadacitinib) has obtained the national health insurance benefit.
The Health Insurance Review and Assessment Service (HIRA) on Thursday held a meeting of the Drug Reimbursement Evaluation Committee and released the outcomes.
The review committee said Rinvoq was eligible for the insurance benefit. AbbVie Korea won the Ministry of Food and Drug Safety’s approval for Rinvoq as rheumatoid arthritis treatment in June.
